Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235513 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL184776 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234621 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233979 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234757 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL17165029 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL237094 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2135188 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233582 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251708-B1 | METHOD FOR PRODUCING A HIGH-PHENOLIC-CONTENT BIOOIL | THE UNIV OF NEW BRUNSWICK (CA) | 2026-02-11 | — | — | EP | disclosed |
| US-20250213665-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-07-03 | — | — | US | disclosed |
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-06-26 | — | — | US | disclosed |
| CN-119630391-A | Sphingolipid-loaded nanobiological formulation for immunomodulation | 西奈山伊坎医学院 | 2025-03-14 | — | — | CN | disclosed |
| US-20250000086-A1 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | BASF SE (DE) | 2025-01-02 | — | — | US | disclosed |
| CN-118459539-A | Compounds for modulating training immunity and methods of use thereof | 生物治疗探索股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-06-13 | — | — | US | disclosed |
| US-20240172746-A1 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | BASF SE (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4308105-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | Trained Therapeutix Discovery, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4304354-A1 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | BASF SE (DE) | 2024-01-17 | — | — | EP | disclosed |
| EP-2588181-A1 | CATHETER ASSEMBLY | SurModics, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588157-A1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | SurModics, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012096787-A1 | DOUBLE WALL CATHETER FOR DELIVERING THERAPEUTIC AGENT | SURMODICS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120172839-A1 | DOUBLE WALL CATHETER FOR DELIVERING THERAPEUTIC AGENT | BANK OF MONTREAL, AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120165786-A1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | BANK OF MONTREAL, AS COLLATERAL AGENT | 2012-06-28 | — | — | US | disclosed |
| US-20120083733-A1 | CATHETER ASSEMBLY WITH GUARD | BANK OF MONTREAL, AS COLLATERAL AGENT | 2012-04-05 | — | — | US | disclosed |
| WO-2012044913-A1 | CATHETER ASSEMBLY WITH GUARD | SUROMDICS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120004605-A1 | CATHETER ASSEMBLY | BANK OF MONTREAL, AS COLLATERAL AGENT | 2012-01-05 | — | — | US | disclosed |
| WO-2012003296-A1 | CATHETER ASSEMBLY | SURMODICS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003293-A1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | SURMODICS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240172746-A1 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | SGMS1, SGMS2, LIPA | SMN1; SMN2 2964/4885NR5A2 1550/4885NR5A1 188/4885 |
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | APOB, APOL1, SGMS1 | SMN1; SMN2 962/4885NR5A2 2894/4885NR5A1 2980/4885 |
| US-20250000086-A1 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | SGMS1, PTDSS1, PLA2G2C | SMN1; SMN2 3816/4885NR5A2 2857/4885NR5A1 174/4885 |
| US-20250213665-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | CD47, MYD88, IL2 | SMN1; SMN2 1106/4885NR5A2 2541/4885NR5A1 2290/4885 |
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | MYD88, CD74, IRF3 | SMN1; SMN2 4751/4885NR5A2 446/4885NR5A1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.